Addex Therapeutics Ltd ADXN

NAS: ADXN | ISIN: US00654J1079   13/11/2024
8,630 USD (-1,60%)
(-1,60%)   13/11/2024

11 november 2024 · Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 · Persbericht

30 september 2024 · Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update · Persbericht

19 september 2024 · Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit · Persbericht

4 september 2024 · Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

27 augustus 2024 · Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration · Persbericht

22 juli 2024 · Addex’s Partner Discontinues ADX71149 development in Epilepsy · Persbericht

15 juli 2024 · Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) · Persbericht

12 juli 2024 · Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) · Persbericht

1 juli 2024 · Addex Shareholders Approve All Resolutions at Annual General Meeting · Persbericht

6 juni 2024 · Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update · Persbericht

5 juni 2024 · Addex Convenes Annual General Meeting 2024 · Persbericht

31 mei 2024 · Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024 · Persbericht

8 mei 2024 · Addex to Present at Bio€quity Europe 2024 · Persbericht

29 april 2024 · Addex Provides Update on ADX71149 Phase 2 Epilepsy Study · Persbericht

19 april 2024 · Addex to Present at the Swiss Biotech Day 2024 · Persbericht

18 april 2024 · Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update · Persbericht

11 april 2024 · Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 · Persbericht

3 april 2024 · Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders · Persbericht

14 maart 2024 · Addex to Present at the Bio-Europe Spring 2024 Conference · Persbericht

31 januari 2024 · Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. · Persbericht

Mijn selecties